Evidence for a Hypercoagulable State in Women With Ovarian Endometriomas

Qinjiao Wu, Ding Ding, Xishi Liu, Sun-Wei Guo, Sun‐Wei Guo
Reproductive sciences (Thousand Oaks, Calif.) · 2015 · vol. 22(9) , pp. 1107–1114 · doi:10.1177/1933719115572478 · PMID:25701841 · W2170650755
article OA: closed CC0 ⤵ 47 in-corpus citations
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06+body, 2026-06-08 ⓘ

Women with ovarian endometriomas exhibited shortened APTT and TT, elevated fibrinogen, and increased activated platelets, suggesting a hypercoagulable state potentially linked to inflammation.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-09 · read from full text ⓘ

This paper tested the hypothesis that women with ovarian endometriomas/endometriosis have a hypercoagulable state by examining peripheral coagulation parameters and platelet activation. In one cohort of 50 premenopausal women with endometriosis matched to 50 healthy controls, the authors measured prothrombin time, activated partial thromboplastin time (APTT), thrombin time, fibrinogen, and other coagulation factors, and in a second cohort assessed the percentage of activated circulating platelets, with platelet activation re-evaluated one month after surgical removal of lesions in those patients. Women with endometriosis had significantly shortened APTT and thrombin time and elevated fibrinogen, along with a higher percentage of circulating degra­nulated/activated platelets; the activated platelet percentage decreased 1 month after surgery. This paper is centrally about endometriosis — it reports altered coagulation markers and increased platelet activation consistent with hypercoagulability in women with ovarian endometriomas/endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 9,845 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Endometriosis is a hormonal disease and also an inflammatory condition. Converging evidence indicates that inflammation and coagulation are 2 major host-defense systems that interact with each other. This study was undertaken to test the hypothesis that women with ovarian endometriomas are in a hypercoagulable state as manifested by the altered procoagulant factors and higher percentage of activated platelets in their peripheral blood. Two sets of participants were recruited. The first set consisted of 50 premenopausal women with endometriosis and 50 age-matched healthy women, and the second set consisted of 21 women with endometriosis and 17 age-comparable women without endometriosis. For the first set, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen, and other coagulation factors, along with their demographic, clinical, and anthropometric data, were measured/retrieved. For the second set, only the percentage of activated platelets in peripheral blood was evaluated. We found that women with endometriosis had a significantly shortened APTT and TT and elevated fibrinogen levels as compared with controls. They also had significantly higher percentage of circulating degranuated platelets, and the percentage was significantly reduced 1 month after surgical removal of endometriotic lesions. These findings provide evidence of a hypercoagulable state in women with endometriosis, reflecting the intimate relationship between coagulation and inflammation. They also suggest that these coagulation parameters such as APTT and fibrinogen and others could potentially be used for diagnostic or prognostic purposes. It also underpins the possibility for the use of antithrombotic therapy in the treatment of endometriosis. Similar content being viewed by others

References

Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389–2398. Taylor HS, Osteen KG, Bruner-Tran KL, et al. Novel therapies targeting endometriosis. Reprod Sci. 2011;18(9):814–823. Guo SW. An overview of the current status of clinical trials on endometriosis: issues and concerns. Fertil Steril. 2014;101(1):183–190. e4. May KE, Conduit-Hulbert SA, Villar J, Kirtley S, Kennedy SH, Becker CM. Peripheral biomarkers of endometriosis: a systematic review. Hum Reprod Update. 2010;16(6):651–674. Bulun SE, Lin Z, Imir G, et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. Pharmacol Rev. 2005;57(3):359–383. Burney RO, Giudice LC. Pathogenesis and pathophysiology of endometriosis. Fertil Steril. 2012;98(3):511–519. Petaja J. Inflammation and coagulation. An overview. Thromb Res. 2011;127(suppl 2):S34–S37. Lipinski S, Bremer L, Lammers T, Thieme F, Schreiber S, Rosenstiel P. Coagulation and inflammation. Molecular insights and diagnostic implications. Hamostaseologie. 2011;31(2):94–102. Demetz G, Ott I. The interface between inflammation and coagulation in cardiovascular disease. Int J Inflam. 2012;2012:860301. Sreeramkumar V, Adrover JM, Ballesteros I, et al. Neutrophils scan for activated platelets to initiate inflammation. Science. 2014;346(6214):1234–1238. Krikun G, Schatz F, Taylor H, Lockwood CJ. Endometriosis and tissue factor. Ann N Y Acad Sci. 2008;1127:101–105. Krikun G. Endometriosis, angiogenesis and tissue factor. Scientifica (Cairo). 2012;2012:306830. Gilabert-Estelles J, Castello R, Gilabert J, et al. Plasminogen activators and plasminogen activator inhibitors in endometriosis. Front Biosci. 2005;10:1162–1176. Osuga Y, Hirota Y, Yoshino O, Hirata T, Koga K, Taketani Y. Proteinase-activated receptors in the endometrium and endometriosis. Front Biosci (Schol Ed). 2012;4:1201–1212. Ding D, Liu X, Duan J, Guo SW. Platelets are a unindicted culprit in the development of endometriosis: Clinical and experimental evidence. Hum Reprod. 2015;30(4):812–832. Braune S, Walter M, Schulze F, Lendlein A, Jung F. Changes in platelet morphology and function during 24 hours of storage. Clin Hemorheol Microcirc. 2014;58(1):159–170. Sun D, Popescu NI, Raisley B, et al. Bacillus anthracis peptido-glycan activates human platelets through FcgammaRII and complement. Blood. 2013;122(4):571–579. Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol. 1985;101(3):880–886. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013. Korte W, Clarke S, Lefkowitz JB. Short activated partial throm-boplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol. 2000;113(1):123–127. Zwaginga JJ, Koomans HA, Sixma JJ, Rabelink TJ. Thrombus formation and platelet-vessel wall interaction in the nephrotic syndrome under flow conditions. J Clin Invest. 1994;93(1):204–211. Kurata M, Sasayama Y, Yamasaki N, Kitazawa I, Hamada Y, Horii I. Mechanism for shortening PT and APTT in dogs and rats–effect of fibrinogen on PT and APTT. J Toxicol Sci. 2003;28(5):439–443. Acang N, Jalil FD. Hypercoagulation in diabetes mellitus. Southeast Asian J Trop Med Public Health. 1993;24(suppl 1):263–266. Zhao Y, Zhang J, Wu J. Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One. 2011;6(1):e16470. Anand SS, Yi Q, Gerstein H, et al. Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation. 2003;108(4):420–425. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med. 2007;262(2):157–172. Ndrepepa G, Braun S, King L, et al. Relation of fibrinogen level with cardiovascular events in patients with coronary artery disease. Am J Cardiol. 2013;111(6):804–810. Gardner SY, Lehmann JR, Costa DL. Oil fly ash-induced elevation of plasma fibrinogen levels in rats. Toxicol Sci. 2000;56(1):175–180. Page RC, Schroeder HE. Pathogenesis of inflammatory periodontal disease. a summary of current work. Lab Invest. 1976;34(3):235–249. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(10):982–988. Bruse C, Bergqvist A, Carlstrom K, Fianu-Jonasson A, Lecander I, Astedt B. Fibrinolytic factors in endometriotic tissue, endometrium, peritoneal fluid, and plasma from women with endometriosis and in endometrium and peritoneal fluid from healthy women. Fertil Steril. 1998;70(5):821–826. Bruse C, Radu D, Bergqvist A. In situ localization of mRNA for the fibrinolytic factors uPA, PAI-1 and uPAR in endometriotic and endometrial tissue. Mol Hum Reprod. 2004;10(3):159–166. Gilabert-Estelles J, Ramon LA, Espana F, Gilabert J, Castello R, Estelles A. Expression of the fibrinolytic components in endometriosis. Pathophysiol Haemost Thromb. 2006;35(1–2):136–140. Braza-Boils A, Mari-Alexandre J, Gilabert J, et al. MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors. Hum Reprod. 2014;29(5):978–88. Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ. Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis. 2010;21(5):459–463. Mina A, Favaloro EJ, Mohammed S, Koutts J. A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis. 2010;21(2):152–157. Mina A, Favaloro EJ, Koutts J. Relationship between short activated partial thromboplastin times, thrombin generation, procoagulant factors and procoagulant phospholipid activity. Blood Coagul Fibrinolysis. 2012;23(3):203–207. Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM. A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood. 2004;104(12):3631–3634. Madi AM, Greci LS, Nawaz H, Katz DL. The activated partial thromboplastin time in early diagnosis of myocardial infarction. Blood Coagul Fibrinolysis. 2001;12(6):495–499. Lippi G, Franchini M, Targher G, et al. Epidemiological association between fasting plasma glucose and shortened APTT. Clin Biochem. 2009;42(1–2):118–120. Mikhailidis DP, Barradas MA, Maris A, Jeremy JY, Dandona P. Fibrinogen mediated activation of platelet aggregation and throm-boxane A2 release: pathological implications in vascular disease. J Clin Pathol. 1985;38(10):1166–1171. Mause SF, Weber C. Microparticles: protagonists of a novel communication network for intercellular information exchange. Circ Res. 2010;29(107):1047–1057. Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res. 1987;47(6):647–656. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1999;33(3):634–639. Michelson AD, Barnard MR, Krueger LA, Frelinger AL III, Furman MI. Evaluation of platelet function by flow cytometry. Methods. 2000;21(3):259–270. Guo SW, Ding D, Geng JG, Wang L, Liu X. P-selectin as a therapeutic target for endometriosis. Fertil Steril. 2015;103(4):990–1000. Krikun G, Hu Z, Osteen K, et al. The immunoconjugate ‘‘icon’’ targets aberrantly expressed endothelial tissue factor causing regression of endometriosis. Am J Pathol. 2010;176(2):1050–1056. Author information Authors and Affiliations Corresponding author Rights and permissions About this article Cite this article Wu, Q., Ding, D., Liu, X. et al. Evidence for a Hypercoagulable State in Women With Ovarian Endometriomas. Reprod. Sci. 22, 1107–1114 (2015). https://doi.org/10.1177/1933719115572478 Published: Issue date: DOI: https://doi.org/10.1177/1933719115572478

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715

MeSH descriptors

Blood Coagulation Endometriosis Platelet Activation Thrombophilia Adult Biomarkers Biomarkers Case-Control Studies Endometriosis Endometriosis Endometriosis Endometriosis Female Fibrinogen Fibrinogen Humans Laparoscopy Middle Aged Partial Thromboplastin Time Platelet Count

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (48)

Cited by (47)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:18:04.362919+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK